Latest Articles

Publication Date
Kate Middleton and King Charles's cancer diagnosis: Understanding cancer, treatment plans and what experts - The Economic Times

Kate Middleton and King Charles's cancer diagnosis: Understanding cancer, treatment plans and what experts The Economic Times

Published: March 24, 2024, 7 a.m.
Data May Support Pembrolizumab/Chemo as New SOC in Endometrial Cancer - Cancer Network

Data May Support Pembrolizumab/Chemo as New SOC in Endometrial Cancer Cancer Network

Published: March 21, 2024, 7 a.m.
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network

Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network

Published: March 21, 2024, 7 a.m.
Before My Mom's Diagnosis, I Knew Nothing About Endometrial Cancer, Here’s What I Learned - Essence

Before My Mom's Diagnosis, I Knew Nothing About Endometrial Cancer, Here’s What I Learned Essence

Published: March 20, 2024, 7 a.m.
Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer - Oncology News Central

Immunotherapy Data “Very Much Practice-Changing” in Endometrial Cancer Oncology News Central

Published: March 20, 2024, 7 a.m.
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - Medpage Today

Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer Medpage Today

Published: March 19, 2024, 7 a.m.
Studying Endometrial Cancer in Black Women - news.med.miami.edu

Studying Endometrial Cancer in Black Women news.med.miami.edu

Published: March 18, 2024, 7 a.m.
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer - OncLive

Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer OncLive

Published: March 18, 2024, 7 a.m.
GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data - BioSpace

GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data BioSpace

Published: March 18, 2024, 7 a.m.
AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain - FiercePharma

AstraZeneca, GSK make case for broad immunotherapy uses in endometrial cancer. But questions remain FiercePharma

Published: March 18, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!